Clinical data | |
---|---|
Pronunciation | /ˈkæptəprɪl/ |
Trade names | Capoten, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682823 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 70–75% |
Metabolism | Liver |
Elimination half-life | 1.9 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.057.806 |
Chemical and physical data | |
Formula | C9H15NO3S |
Molar mass | 217.28 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Captopril, sold under the brand name Capoten among others, is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure. Captopril was the first oral ACE inhibitor found for the treatment of hypertension.[3] It does not cause fatigue as associated with beta-blockers. Due to the adverse drug event of causing hyperkalemia, as seen with most ACE Inhibitors, the medication is usually paired with a diuretic.[citation needed]
Captopril was patented in 1976 and approved for medical use in 1980.[4]